Schools

Dobbin, S. J. H., Mangion, K., Berry, C., Roditi, G., Basak, S., McClure, J. D., Brooksbank, K., Sonecki, P., Sourbron, S., Evans, J., White, J., Welsh, P., Butler, E., Venugopal, B., Touyz, R. M., Jones, R. J., Petrie, M. C., Lang, N. N. (2025) Vascular endothelial growth factor inhibitor-induced cardiotoxicity: prospective multimodality assessment incorporating cardiovascular magnetic resonance imaging. Heart, (doi: 10.1136/heartjnl-2024-325535)

Pinar, S. A., McGuigan, M.-C., Duthie, F., Ezhil, A., Holroyd, D., Jamieson, N. B. (2025) A case report of sarcomatoid carcinoma of the common bile duct with a review of the literature. World Journal of Surgical Oncology,

van Duuren, P., Wieringa, T. H., Duiverman, M., Witjes, M., Snijder, A., Welisch, G., Smykowski, A., Keith, N. (2025) Reimagining Patient Involvement in Research. (doi: 10.17605/OSF.IO/5H9DY)

Rangelova, E. et al. (2024) The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Annals of Oncology, (doi: 10.1016/j.annonc.2024.12.015)

MacDonald, L. et al. (2024) Synovial tissue myeloid dendritic cell subsets exhibit distinct tissue-niche localization and function in health and rheumatoid arthritis. Immunity, 57, pp. 2843-2862.e12. (doi: 10.1016/j.immuni.2024.11.004)

McGuigan, M.-C., Hadjicosti, R., Cameron, A. J., Coats, M., Chang, D., Dickson, E. J., Holroyd, D., McKay, C. J., Jamieson, N. B. (2024) The surveillance strategy for Intraductal Pancreatic Mucinous Neoplasms: Criteria for discontinuation. Annals of Surgery, (doi: 10.1097/SLA.0000000000006580)

Lucocq, J. et al. (2024) Precursor epithelial subtypes of adenocarcinoma arising from intraductal papillary mucinous neoplasms (A-IPMN): clinicopathological features, recurrence and response to adjuvant chemotherapy. Annals of Surgical Oncology, 31, pp. 7023-7032. (doi: 10.1245/s10434-024-15677-z)

Keith, N. et al. (2024) Emerging Ecologies of Health, Heritage, and Habitat: Looking into Living and Working in 2033. (doi: 10.17605/OSF.IO/BTNZ9)

Pereira, B. A. et al. (2024) Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Science Advances, 10, (doi: 10.1126/sciadv.adl1197)

McKenzie, M., Lian, G.-Y., Pennel, K. A.F., Quinn, J. A., Jamieson, N. B., Edwards, J. (2024) NFκB signalling in colorectal cancer: examining the central dogma of IKKα and IKKβ signalling. Heliyon, 10, (doi: 10.1016/j.heliyon.2024.e32904)

Kendall, T., Overi, D., Guido, M., Braconi, C., Banales, J., Cardinale, V., Gaudio, E., Groot Koerkamp, B., Carpino, G. (2024) Recommendations on maximising the clinical value of tissue in the management of patients with intrahepatic cholangiocarcinoma. JHEP Reports, 6, (doi: 10.1016/j.jhepr.2024.101067)

Zanuso, V., Nash, T., Casolino, R., Armstrong, G., Pallise, O., Milne, J., Braconi, C. (2024) Insights for clinical management from the real-life data of the centralized West of Scotland biliary cancer clinic. BMC Cancer, 24, (doi: 10.1186/s12885-024-12279-6)

Boey, A., Bryce, A., Dickson, E., Coats, M., McKay, C., Jamieson, N., Chang, D., Holroyd, D., Dreyer, S. (2024) The Impact of Pre-operative Indeterminate Lung Nodules in the Surgical Management of Pancreatic Ductal Adenocarcinoma. (doi: 10.1016/j.hpb.2024.03.269)

Robertson, F. P., Cameron, A., Spiers, H. V.M., Joseph, N., Taylor, E., Ratnayake, B., Jamieson, N. B., Pandanaboyana, S. (2024) Evidence for molecular subtyping in pancreatic ductal adenocarcinoma: A systematic review. HPB, 26, pp. 609-617. (doi: 10.1016/j.hpb.2024.02.001)

Keith, N., Ross, K., Campbell, H., McCrum, P., Uribe, V., Rowan, F. (2024) Designing Future Experiences: The value of exhibition spaces as creative environments for collaborative, multidisciplinary research, exhibitions, and audiences. (doi: 10.17605/OSF.IO/N7MD9)

Lucocq, J. et al. (2024) Adjuvant chemotherapy for adenocarcinoma arising from intraductal papillary mucinous neoplasia: multicentre ADENO-IPMN study. British Journal of Surgery, 111, (doi: 10.1093/bjs/znae100)

Dickson, A. L., Zickuhr, G. M., Um, I. H., Zhang, Y., Plummer, R., Blagden, S. P., Symeonides, S. N., Cook, N., Evans, T.R. J., Elshani, M., Harrison, D. J. (2024) Exposing the heterogeneity of the lipidome in the TME of cutaneous melanoma following treatment with NUC-7738 in combination with anti-PD-1 therapy. (doi: 10.1158/1538-7445.am2024-6222)

Sacco, J. J., Jackson, R., Corrie, P., Danson, S., Evans, J., Ochsenreither, S., Kumar, S., Goodman, A., Larkin, J., Karydis, I., Steven, N., Lorigan, P., Plummer, R., Patel, P., Psarelli, E., Olsson-Brown, A., Shaw, H., Leyvraz, S., Handley, L., Rawcliffe, C., Nathan, P. (2024) A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma. European Journal of Cancer, 202, (doi: 10.1016/j.ejca.2024.114009)

Pennel, K. A.F. et al. (2024) JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors. Journal of Experimental and Clinical Cancer Research, 43, (doi: 10.1186/s13046-024-02958-4)

Bouttell, J., Fraser, H., Goodlad, J. R., Hopkins, D., McKay, P., Oien, K. A., Seligmann, B., Von Delft, S., Hawkins, N. (2024) Adding a gene expression profile test to aid differential diagnosis and treatment in aggressive large B-cell lymphoma: an early exploratory economic evaluation. Applied Health Economics and Health Policy, 22, pp. 243-254. (doi: 10.1007/s40258-023-00845-1)

O’Rourke, C. J. et al. (2024) Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy. Gut, 73, pp. 496-508. (doi: 10.1136/gutjnl-2023-330748)

McGovern, J., Mackay, C., Freireich, R., Golder, A. M., Dolan, R. D., Horgan, P. G., Holroyd, D., Jamieson, N. B., McMillan, D. C. (2024) The relationship between liver volume, clinicopathological characteristics and survival in patients undergoing resection with curative intent for non-metastatic colonic cancer. Tomography, 10, pp. 349-359. (doi: 10.3390/tomography10030027)

Bryce, A., Dreyer, S., Dolan, R., Froeling, F., Chang, D. (2024) Host phenotypic adversity independently predicts progression to resection in neoadjuvantly-treated pancreatic cancer. (doi: 10.1016/j.ejso.2023.107753)

Dreyer, S., Bryce, A., Australian Pancreatic Cancer Genome Initiative, , Biankin, A., Jamieson, N., Chang, D. (2024) The clinical and molecular landscape of early onset pancreatic cancer. (doi: 10.1016/j.ejso.2023.107348)

Frei, A. L. et al. (2024) Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II–III colorectal cancer from the SCOT and QUASAR 2 trials: A retrospective analysis. Lancet Oncology, 25, pp. 198-211. (doi: 10.1016/S1470-2045(23)00560-0)

Welisch, G., Keith, N., Jones, R., Hanna, C. (2024) Creative approaches to reimagining patient and public involvement (PPI) in cancer research. (doi: 10.17605/OSF.IO/243XN)

Shamis, S. A. K., Savioli, F., Ammar, A., Al-Badran, S. S.F., Hatthakarnkul, P., Leslie, H., Mallon, E., Jamieson, N. B., McMillan, D. C., Edwards, J. (2024) Spatial transcriptomic analysis of tumour with high and low CAIX expression in TNBC tissue samples using GeoMx™ RNA assay. Histology and Histopathology: Cellular and Molecular Biology, 39, pp. 177-200. (doi: 10.14670/HH-18-655)

Keith, N., Donaldson, M. (2024) Professional and Technical Staff supporting Open Research: Case Study 4. Research-enabling staff and Open Research.

Skeldon, K. et al. (2023) Research Firsts Exhibition. (doi: 10.17605/OSF.IO/ZQC5P)

McLaren, A. S., Spoor, J. A., Cartwright, D., Naylor, G., Barclay, S., Priest, M., Puttagunta, S., Armstrong, K., Ballantyne, S., Stanley, A., Evans, T. R. J., West of Scotland HCC MDT, (2023) Impact of the COVID-19 pandemic on patients with hepatocellular carcinoma in the west of Scotland: a cohort study. BMJ Open Gastroenterology, 10, (doi: 10.1136/bmjgast-2023-001231)

Lucocq, J. et al. (2023) Risk of recurrence after surgical resection for adenocarcinoma arising from intraductal papillary mucinous neoplasia (IPMN) with patterns of distribution and treatment. Annals of Surgery, 280, pp. 126-135. (doi: 10.1097/sla.0000000000006144)

Zanuso, V., Rimassa, L., Braconi, C. (2023) The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy. Hepatology, (doi: 10.1097/HEP.0000000000000572)

Haddad, T. S., van den Dobbelsteen, L., Öztürk, S. K., Geene, R., Nijman, I. J., Verrijp, K., Jamieson, N. B., Wood, C., van Vliet, S., Reuvers, L., Achouiti, S., Rutgers, N., Brouwer, N., Simmer, F., Zlobec, I., Lugli, A., Nagtegaal, I. D. (2023) Pseudobudding: ruptured glands do not represent true tumor buds. Journal of Pathology, 261, pp. 19-27. (doi: 10.1002/path.6146)

Kristeleit, R., Plummer, R., Jones, R., Carter, L., Blagden, S., Sarker, D., Arkenau, T., Evans, T. R. J., Danson, S., Symeonides, S. N., Veal, G. J., Klencke, B. J., Kowalski, M. M., Banerji, U. (2023) A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. British Journal of Cancer, 129, pp. 38-45. (doi: 10.1038/s41416-023-02279-x)

Solovyeva, O., Dimairo, M., Weir, C. J., Hee, S. W., Espinasse, A., Ursino, M., Patel, D., Kightley, A., Hughes, S., Jaki, T., Mander, A., Evans, T. R. J., Lee, S., Hopewell, S., Rantell, K. R., Chan, A.-W., Bedding, A., Stephens, R., Richards, D., Roberts, L., Kirkpatrick, J., de Bono, J., Yap, C. (2023) Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study. BMC Medicine, 21, (doi: 10.1186/s12916-023-02937-0)

Pennel, K., Morrow, E., Hatthakarnkul, P., Leslie, H., Mallon, E., Andersen, D., Jamieson, N., McMillan, D., Roseweir, A., Edwards, J. (2023) High expression of STAT3 within the tumour-associated stroma predicts poor outcome in breast cancer patients. Cancer Medicine, 12, pp. 13225-13240. (doi: 10.1002/cam4.6014)

Hamid, O., Hassel, J. C., Shoushtari, A. N., Meier, F., Bauer, T. M., Salama, A. K.S., Kirkwood, J. M., Ascierto, P. A., Lorigan, P. C., Mauch, C., Orloff, M., Evans, T. R. J., Holland, C., Edukulla, R., Abedin, S. E., Middleton, M. R. (2023) Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. Journal for ImmunoTherapy of Cancer, 11, (doi: 10.1136/jitc-2023-006747)

Sykes, R. A., Neves, K. B., Alves-Lopes, R., Caputo, I., Jamieson, N. B., Kamdar, A., Legrini, A., Leslie, H., McIntosh, A., McConnachie, A., Morrow, A., McFarlane, R. W., Mangion, K., McAbney, J., Montezano, A. C., Touyz, R. M., Wood, C., Berry, C. (2023) Vascular mechanisms of post-COVID-19 conditions: rho-kinase is a novel target for therapy. European Heart Journal: Cardiovascular Pharmacotherapy, 9, pp. 371-386. (doi: 10.1093/ehjcvp/pvad025)

McGovern, J., Leadbitter, S., Miller, G., Hounat, A., Kamande, I., Dolan, R. D., Horgan, P. G., Chang, D. K., Jamieson, N. B., McMillan, D. C. (2023) The relationship between heart rate variability and TNM stage, co-morbidity, systemic inflammation and survival in patients with primary operable colorectal cancer. Scientific Reports, 13, (doi: 10.1038/s41598-023-35396-x)

Wood, C. S., Pennel, K. A.F., Leslie, H., Legrini, A., Cameron, A. J., Melissourgou-Syka, L., Quinn, J. A., van Wyk, H. C., Hay, J., Roseweir, A. K., Nixon, C., Roxburgh, C. S.D., McMillan, D. C., Biankin, A. V., Sansom, O. J., Horgan, P. G., Edwards, J., Steele, C. W., Jamieson, N. B. (2023) Spatially resolved transcriptomics deconvolutes prognostic histological subgroups in patients with colorectal cancer and synchronous liver metastases. Cancer Research, 83, pp. 1329-1344. (doi: 10.1158/0008-5472.CAN-22-2794)

Vita, F., Olaizola Rebè, I., Amato, F., Rae, C., Marco, S., Banales, J. M., Braconi, C. (2023) Heterogeneity of cholangiocarcinoma immune biology. Cells, 12, (doi: 10.3390/cells12060846)

Espinasse, A., Solovyeva, O., Dimairo, M., Weir, C., Jaki, T., Mander, A., Kightley, A., Evans, J., Lee, S., Bedding, A., Hopewell, S., Rantell, K., Liu, R., Chan, A.-W., De Bono, J., Yap, C. (2023) SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: the DEFINE (DosE-FIndiNg Extensions) study protocol. BMJ Open, 13, (doi: 10.1136/bmjopen-2022-068173)

Keith, N. et al. (2023) Regenerative Futures: From Global to Local Development in 2032. (doi: 10.36399/gla.pubs.295862)

Dreyer, S. B., Rae, S., Bisset, K., Upstill-Goddard, R., Gemenetzis, G., Johns, A. L., Australian Pancreatic Cancer Genome Initiative3,, , Glasgow Precision Oncology Laboratory1, , Dickson, E. J., Mittal, A., Gill, A. J., Duthie, F., pea, A., Lawlor, R. T., Scarpa, A., Salvia, R., Pulvirenti, A., Zerbi, A., Marchesi, F., McKay, C. J., Biankin, A. V., Samra, J. S., Chang, D. K., Jamieson, N. B. (2023) The impact of molecular subtyping on pathological staging of pancreatic cancer. Annals of Surgery, 277, pp. e396-e405. (doi: 10.1097/SLA.0000000000005050)

Ali, A., Jamieson, N. B., Khan, I. Q., Chang, D., Giovannetti, E., Funel, N., Frampton, A.E., Morton, J., Sansom, O., Evans, T.R.J., Duthie, F., McKay, C. J., Samra, J.S., Gill, A. J., Biankin, A., Oien, K. A. (2022) Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. American Journal of Cancer Research, 12, pp. 5668-5683.

Keith, N., Welisch, G., Ross, K., Smykowski, A. (2022) The Curious Researchers.

Evans, J., Keith, N., Paul, J. (2022) An analysis of Relative Telomere Length (RTL) during peri-operative chemotherapy in patients with operable gastric or gastro-oesophageal junction adenocarcinoma. (doi: 10.17504/protocols.io.ca5csg2w)

Bryce, A. S., Dreyer, S. B., Froeling, F. E.M., Chang, D. K. (2022) Exploring the biology of cancer-associated fibroblasts in pancreatic cancer. Cancers, 14, (doi: 10.3390/cancers14215302)

Fisher, N. C. et al. (2022) Biological misinterpretation of transcriptional signatures in tumour samples can unknowingly undermine mechanistic understanding and faithful alignment with preclinical data. Clinical Cancer Research, 28, pp. 4056-4069. (doi: 10.1158/1078-0432.CCR-22-1102)

Raggi, C., Taddei, M. L., Rae, C., Braconi, C., Marra, F. (2022) Metabolic reprogramming in cholangiocarcinoma. Journal of Hepatology, 77, pp. 849-864. (doi: 10.1016/j.jhep.2022.04.038)

Muñoz‐Martínez, S. et al. (2022) Outcome of liver cancer patients with SARS‐CoV‐2 infection: an international, multicentre, cohort study. Liver International, 42, pp. 1891-1901. (doi: 10.1111/liv.15320)

Khan, K. S., Gall, L. S., Dreyer, S., McCollum, C., Chuntamongkol, R., Craig, C., MacKay, C., Macdonald, A., Forshaw, M. (2022) Stage migration in newly diagnosed oesophagogastric cancer during the first wave of the COVID-19 pandemic. British Journal of Surgery, 109, pp. 773-774. (doi: 10.1093/bjs/znac112)

Seth, S., Forrest, E. H., Morris, J. M., Heydtmann, M., Konanahalli, P., Kohnen, G., Oien, K. A. (2022) Audit of medical (non-targeted) liver biopsy specimen quality, pathology reporting and effect on patient management. Journal of Clinical Pathology, 75, pp. 498-502. (doi: 10.1136/jclinpath-2020-207366)

Sala, A., Cameron, J. M., Jenkins, C. A., Barr, H., Christie, L., Conn, J. J.A., Evans, T. R. J., Harris, D. A., Palmer, D. S., Rinaldi, C., Theakstone, A. G., Baker, M. J. (2022) Liquid biopsy for pancreatic cancer detection using infrared spectroscopy. Cancers, 14, (doi: 10.3390/cancers14133048)

Evans, J., Keith, N., Paul, J. (2022) An analysis of Relative Telomere Length (RTL) during chemotherapy in patients with advanced gastro-oesophageal adenocarcinoma. (doi: 10.17504/protocols.io.n92ldznenv5b/v1)

CHOLECOVID Collaborative, (2022) Global overview of the management of acute cholecystitis during the COVID-19 pandemic (CHOLECOVID study) BJS Open, 6, (doi: 10.1093/bjsopen/zrac052)

Colyn, L. et al. (2022) New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming. Journal of Experimental and Clinical Cancer Research, 41, (doi: 10.1186/s13046-022-02386-2)

Casolino, R. et al. (2022) Bridging the equity gap in patient education: the biliary tract cancer BABEL project. Lancet Oncology, 23, pp. 568-570. (doi: 10.1016/S1470-2045(22)00143-7)

Izquierdo-Sanchez, L. et al. (2022) Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. Journal of Hepatology, 76, pp. 1109-1121. (doi: 10.1016/j.jhep.2021.12.010)

Casolino, R., Amato, F., Rae, C., Puttagunta, S., Braconi, C. (2022) Receptor tyrosine kinase co-amplification and benefit from HER2 inhibitors in biliary tract cancers. Journal of Hepatology, 76, pp. 1227-1229. (doi: 10.1016/j.jhep.2022.01.012)

Glen, C., Tan, Y. Y., Waterston, A., Evans, T. R. J., Jones, R. J., Petrie, M. C., Lang, N. N. (2022) Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: CardioOncology state-of-the-art review. JACC: CardioOncology, 4, pp. 1-18. (doi: 10.1016/j.jaccao.2022.01.096)

Dreyer, S. B., Upstill-Goddard, R., Legrini, A., Biankin, A. V., Jamieson, N. B., Chang, D. K. (2022) Genomic and molecular analyses identify molecular subtypes of pancreatic cancer recurrence. Gastroenterology, 162, pp. 320-324.e4. (doi: 10.1053/j.gastro.2021.09.022)

Bouttell, J., Heggie, R., Oien, K., Romaniuk, A., VanSteenhouse, H., von Delft, S., Hawkins, N. (2022) Economic evaluation of genomic/genetic tests: a review and future directions. International Journal of Technology Assessment in Health Care, 38, (doi: 10.1017/S0266462322000484)

Dreyer, S., Upstill-Goddard, R., Legrini, A., Biankin, A., Jamieson, N., Chang, D. (2022) Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. (doi: 10.1016/j.hpb.2022.05.086)

Gemenetzis, G., McKay, S., Pathak, S., Moir, J., Laing, R., Jamieson, N. B., Young, A. L., Chatzizacharias, N. A., Giovinazzo, F., Roberts, K. J. (2021) Surgical management of non-metastatic pancreatic cancer in the United Kingdom: results of a nationwide survey on current practice. Frontiers in Oncology, 11, (doi: 10.3389/fonc.2021.791946)

Meecham, A., Miranda, E., Morris, H. T., Hair, J., Oien, K. A., Gerrard, G., Guppy, N., Mooney, D., Shaw, E. C., Ashton-Key, M., Lees, R., Flanagan, A., Rodriguez-Justo, M. (2021) Alternative tissue fixation for combined histopathological and molecular analysis in a clinically representative setting. Histochemistry and Cell Biology, 156, pp. 595-607. (doi: 10.1007/s00418-021-02029-1)

Pulvirenti, A. et al. (2021) Multi-institutional development and external validation of a nomogram to predict recurrence after curative resection of pancreatic neuroendocrine tumors. Annals of Surgery, 274, pp. 1051-1057. (doi: 10.1097/SLA.0000000000003579)

Carotenuto, P. et al. (2021) Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 12, (doi: 10.1038/s41467-021-27099-6)

McKay, S. C. et al. (2021) Impact of SARS-CoV-2 pandemic on pancreatic cancer services and treatment pathways: United Kingdom experience. HPB, 23, pp. 1656-1665. (doi: 10.1016/j.hpb.2021.03.003)

Lampis, A., Hahne, J. C., Gasparini, P., Cascione, L., Hedayat, S., Vlachogiannis, G., Murgia, C., Fontana, E., Edwards, J., Horgan, P. G., Terracciano, L., Sansom, O. J., Martins, C. D., Kramer-Marek, G., Croce, C. M., Braconi, C., Fassan, M., Valeri, N. (2021) MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer. Cell Death and Differentiation, 28, pp. 2970-2982. (doi: 10.1038/s41418-021-00820-0)

Halle-Smith, J. M., Hall, L., Daamen, L. A., Hodson, J., Pande, R., Young, A., Jamieson, N. B., Lamarca, A., van Santvoort, H. C., Quintus Molenaar, I., Valle, J. W., Roberts, K. J. (2021) Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. European Journal of Surgical Oncology, 47, pp. 2248-2255. (doi: 10.1016/j.ejso.2021.04.031)

Finn, R. S., Kudo, M., Cheng, A.-L., Wyrwicz, L., Ngan, R. K.C., Blanc, J.-F., Baron, A. D., Vogel, A., Ikeda, M., Piscaglia, F., Han, K.-H., Qin, S., Minoshima, Y., Kanekiyo, M., Ren, M., Dairiki, R., Tamai, T., Dutcus, C. E., Ikezawa, H., Funahashi, Y., Evans, T. R. J. (2021) Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: from the phase III REFLECT study. Clinical Cancer Research, 27, pp. 4848-4858. (doi: 10.1158/1078-0432.CCR-20-4219)

Middleton, M. R., Dean, E., Evans, T. R.J., Shapiro, G. I., Pollard, J., Hendriks, B. S., Falk, M., Diaz-Padilla, I., Plummer, R. (2021) Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours. British Journal of Cancer, 125, pp. 510-519. (doi: 10.1038/s41416-021-01405-x)

Casolino, R., Paiella, S., Azzolina, D., Beer, P. A., Corbo, V., Lorenzoni, G., Gregori, D., GOlan, T., Braconi, C., Froeling, F. E.M., Milella, M., Scarpa, A., Pea, A., Malleo, G., Salvia, R., Bassi, C., Chang, D. K., Biankin, A. V. (2021) Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. Journal of Clinical Oncology, 39, pp. 2617-2631. (doi: 10.1200/JCO.20.03238)

Lei, M., Siemers, N. O., Pandya, D., Chang, H., Sanchez, T., Harbison, C., Szabo, P. M., Janjigian, Y., Ott, P. A., Sharma, P., Bendell, J., Evans, T. R. J., de Braud, F., Chau, I., Boyd1, Z. (2021) Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab±Ipilimumab in gastric cancer/gastroesophageal junction cancer. Clinical Cancer Research, 27, pp. 3926-3935. (doi: 10.1158/1078-0432.CCR-20-2790)

Haq, M. I., Drake, T. M., Goh, T. L., Ahmed, A., Forrest, E., Barclay, S., Gillespie, R., Priest, M., Evans, J., Graham, J., Ballantyne, S., McMillan, D. C., Hayes, P. C., Bird, T. G., Stanley, A. J. (2021) Effect of hepatocellular carcinoma surveillance programmes on overall survival in a mixed cirrhotic UK population: a prospective, longitudinal cohort study. Journal of Clinical Medicine, 10, (doi: 10.3390/jcm10132770)

Welisch, G., Twelves, C., Plummer, R., Evans, J., Danson, S., Symeonides, S., Halsey, C., Jones, R., Hanna, C., Gallagher, P., Walls, G., Taylor, K., Barnett, S., Forde, C., White, M., Williams, C., El Badri, S., Chipole, B.'e. D., Keith, N. (2021) First in Human: who and what makes a cancer phase 1 trial and why are they so important? (doi: 10.17605/OSF.IO/KWHQF)

McNamara, M. G., Bridgewater, J., Palmer, D.H., Faluyi, O., Wasan, H., Patel, A., Ryder, W.D., Barber, S., Gnanaranjan, C., Ghazaly, E., Evans, T.R.J., Valle, J.W. (2021) A phase Ib study of NUC-1031 in combination with cisplatin for the first-line treatment of patients with advanced biliary tract cancer (ABC-08) Oncologist, 26, pp. e669-e678. (doi: 10.1002/onco.13598)

Rae, C., Amato, F., Braconi, C. (2021) Patient-derived organoids as a model for cancer drug discovery. International Journal of Molecular Sciences, 22, (doi: 10.3390/ijms22073483)

Annese, V. F., Patil, S. B., Hu, C., Giagkoulovits, C., Al-Rawhani, M. A., Grant, J., Macleod, M., Clayton, D.J., Heaney, L.M., Daly, R., Accarino, C., Shah, Y. D., Cheah, B. C., Beeley, J., Evans, T.R.J., Jones, R., Barrett, M. P., Cumming, D. R.S. (2021) A monolithic single-chip point-of-care platform for metabolomic prostate cancer detection. Microsystems and Nanoengineering, 7, (doi: 10.1038/s41378-021-00243-4)

Keith, N., Plummer, R., Coyle, V., Cameron, D., Evans, J., Twelves, C., Palmer, D., Danson, S., Graham, D., Welisch, G. (2021) Early Phase Cancer Research in the COVID-19 Pandemic: an ECMC North Initiative. (doi: 10.17605/OSF.IO/6WTN2)

Lakis, V. et al. (2021) DNA methylation patterns identify subgroups of pancreatic neuroendocrine tumors with clinical association. Communications Biology, 4, (doi: 10.1038/s42003-020-01469-0)

Jones, C. M., Radhakrishna, G., Aitken, K., Bridgewater, J., Corrie, P., Eatock, M., Goody, R., Ghaneh, P., Good, J., Grose, D., Holyoake, D., Hunt, A., Jamieson, N. B., Palmer, D. H., Soonawalla, Z., Valle, J. W., Hawkins, M. A., Mukherjee, S. (2021) Reply to comment on “The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic” British Journal of Cancer, 124, pp. 679-680. (doi: 10.1038/s41416-020-01133-8)

Casolino, R., Braconi, C., Malleo, G., Paiella, S., Bassi, C., Milella, M., Dreyer, S.B., Froeling, F.E.M., Chang, D.K., Biankin, A.V., Golan, T. (2021) Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Annals of Oncology, 32, pp. 183-196. (doi: 10.1016/j.annonc.2020.11.013)

Dreyer, S. B. et al. (2021) Targeting DNA damage response and replication stress in pancreatic cancer. Gastroenterology, 160, pp. 362-377. (doi: 10.1053/j.gastro.2020.09.043)

Pea, A., Jamieson, N. B., Braconi, C. (2021) Biology and clinical application of regulatory RNAs in hepatocellular carcinoma. Hepatology, 73, pp. 38-48. (doi: 10.1002/hep.31225)

Ofoeyeno, N., Ekpenyong, E., Braconi, C. (2021) Pathogenetic role and clinical implications of regulatory RNAs in biliary tract cancer. Cancers, 13, (doi: 10.3390/cancers13010012)

Clark, R., Bell, S., Roccisana, J., Oien, K. A., Sneddon, S. F. (2021) Creation of a novel simple heat mapping method for curriculum mapping, using pathology teaching as the exemplar. BMC Medical Education, 21, (doi: 10.1186/s12909-021-02808-3)

Moekotte, A. L., Lof, S., Van Roessel, S., Fontana, M., Dreyer, S., Shablak, A., Casciani, F., Mavroeidis, V. K., Robinson, S., Khalil, K., Gradinariu, G., Mowbray, N., Al-Sarireh, B., Fusai, G. K., Roberts, K., White, S., Soonawalla, Z., Jamieson, N. B., Salvia, R., Besselink, M. G., Abu Hilal, M. (2020) Histopathologic predictors of survival and recurrence in resected ampullary adenocarcinoma. Annals of Surgery, 272, pp. 1086-1093. (doi: 10.1097/SLA.0000000000003177)

Middleton, M. R., McAlpine, C., Woodcock, V. K., Corrie, P., Infante, J. R., Steven, N. M., Evans, T. R. J., Anthoney, A., Shoushtari, A. N., Hamid, O., Gupta, A., Vardeu, A., Leach, E., Naidoo, R., Stanhope, S., Lewis, S., Hurstb, J., O’Kelly, I., Sznol, M. (2020) Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clinical Cancer Research, 26, pp. 5869-5878. (doi: 10.1158/1078-0432.CCR-20-1247)

Kristeleit, R. et al. (2020) Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours. British Journal of Cancer, 123, pp. 1360-1369. (doi: 10.1038/s41416-020-1010-8)

Marin, J. J. G., Prete, M. G., Lamarca, A., Tavolari, S., Landa-Magdalena, A., Brandi, G., Segatto, O., Vogel, A., Macias, R. I. R., Rodrigues, P. M., Casta, A. L., Mertens, J., Rodrigues, C. M. P., Fernandez-Barrena, M. G., Da Silva Ruivo, A., Marzioni, M., Mentrasti, G., Acedo, P., Munoz-Garrido, P., Cardinale, V., Banales, J. M., Valle, J. W., Bridgewater, J., Braconi, C. (2020) Current and novel therapeutic opportunities for systemic therapy in biliary cancer. British Journal of Cancer, 123, pp. 1047-1059. (doi: 10.1038/s41416-020-0987-3)

Bailey, M. H. et al. (2020) Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nature Communications, 11, (doi: 10.1038/s41467-020-18151-y)

Ivanova, Y., Aitchison, I., Cannon, P., Butler, D., Gadegaard, N., Keith, N. (2020) Mapping of University Research Output and Impact to the United Nations Sustainable Development Goals. (doi: 10.17605/OSF.IO/UFYTA)

Jones, C. M., Radhakrishna, G., Aitken, K., Bridgewater, J., Corrie, P., Eatock, M., Goody, R., Ghaneh, P., Good, J., Grose, D., Holyoake, D., Hunt, A., Jamieson, N. B., Palmer, D. H., Soonawalla, Z., Valle, J. W., Hawkins, M. A., Mukherjee, S. (2020) Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. British Journal of Cancer, 123, pp. 709-713. (doi: 10.1038/s41416-020-0980-x)

Moekotte, A. L. et al. (2020) Development and external validation of a prediction model for survival in patients with resected ampullary adenocarcinoma. European Journal of Surgical Oncology, 46, pp. 1717-1726. (doi: 10.1016/j.ejso.2020.04.011)

Carotenuto, P. et al. (2020) Modulation of biliary cancer chemo‐resistance through microRNA‐mediated rewiring of the expansion of CD133+ cells. Hepatology, 72, pp. 982-996. (doi: 10.1002/hep.31094)

Li, C. H. et al. (2020) Sex differences in oncogenic mutational processes. Nature Communications, 11, (doi: 10.1038/s41467-020-17359-2)

Moekotte, A.L. et al. (2020) Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study. British Journal of Surgery, 107, pp. 1171-1182. (doi: 10.1002/bjs.11555)

Sarker, D., Plummer, R., Meyer, T., Sodergren, M. H., Basu, B., Chee, C. E., , (2020) MTL-CEBPA, a small activating RNA therapeutic upregulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multicenter, open-label, phase I trial. Clinical Cancer Research, 26, pp. 3936-3946. (doi: 10.1158/1078-0432.CCR-20-0414)

Dreyer, S. B. et al. (2020) Precision oncology in surgery: patient selection for operable pancreatic cancer. Annals of Surgery, 272, pp. 366-376. (doi: 10.1097/SLA.0000000000003143)

Briggs, A., Daniele, B., Dick, K., Evans, T. R. J., Galle, P. R., Hubner, R. A., Lopez, C., Siebert, U., Tremblay, G. (2020) Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. British Journal of Cancer, 122, pp. 1754-1759. (doi: 10.1038/s41416-020-0817-7)

Corrie, P.G. et al. (2020) Scheduling nab-paclitaxel combined with gemcitabine as first line treatment for metastatic pancreatic adenocarcinoma. British Journal of Cancer, 122, pp. 1760-1768. (doi: 10.1038/s41416-020-0846-2)

McNamara, M. G., Goyal, L., Doherty, M., Springfeld, C., Cosgrove, D., Sjoquist, K. M., Park, J. O., Verdaguer, H., Braconi, C., Ross, P., Gramont, A. D., Zalcberg, J. R., Palmer, D. H., Valle, J. W., Knox, J. J. (2020) NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121) Future Oncology, 16, pp. 1069-1081. (doi: 10.2217/fon-2020-0247)

Brunton, H. et al. (2020) HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Reports, 31, (doi: 10.1016/j.celrep.2020.107625)

Litchfield, K. et al. (2020) Representative sequencing: unbiased sampling of solid tumor tissue. Cell Reports, 31, (doi: 10.1016/j.celrep.2020.107550)

Amato, F., Rae, C., Prete, M. G., Braconi, C. (2020) Cholangiocarcinoma disease modelling through patients derived organoids. Cells, 9, (doi: 10.3390/cells9040832)

The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, , Bailey, P. J., Chang, D. K., Cooke, S. L., Biankin, A. V., Duthie, F. R., Graham, J. S., Jamieson, N. B., Musgrove, E. A., Martin, S., Yuan, K., Wright, D. W., Oien, K. A. (2020) Pan-cancer analysis of whole genomes. Nature, 578, pp. 82-93. (doi: 10.1038/s41586-020-1969-6)

Alsina, A., Kudo, M., Vogel, A., Cheng, A.-L., Tak, W. Y., Ryoo, B.-Y., Evans, T. R. J., López López, C., Daniele, B., Misir, S., Ren, M., Izumi, N., Qin, S., Finn, R. S. (2020) Effects of subsequent systemic anticancer medication following first-line lenvatinib: a post hoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma. Liver Cancer, 9, pp. 93-104. (doi: 10.1159/000504624)

RIFT Study Group, (2020) Evaluation of appendicitis risk prediction models in adults with suspected appendicitis. British Journal of Surgery, 107, pp. 73-86. (doi: 10.1002/bjs.11440)

Dreyer, S.B., Jamieson, N.B., Cooke, S.L., Valle, J.W., McKay, C.J., Biankin, A.V., Chang, D.K. (2020) PRECISION-Panc: the next generation therapeutic development platform for pancreatic cancer. Clinical Oncology, 32, pp. 1-4. (doi: 10.1016/j.clon.2019.07.011)

Dreyer, S.B., Jamieson, N.B., Morton, J.P., Sansom, O.J., Biankin, A.V., Chang, D.K. (2020) Pancreatic cancer: from genome discovery to PRECISION-Panc. Clinical Oncology, 32, pp. 5-8. (doi: 10.1016/j.clon.2019.08.007)

Cebon, J. S. et al. (2020) Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. Journal for ImmunoTherapy of Cancer, 8, (doi: 10.1136/jitc-2019-000410)

Driskell, O. J., Lee, J. L., Oien, K. A., Hall, A., Verrill, C., CM-Path QA Panel, . (2019) Pathology and regulation for research in the UK: An overview [version 2; peer review: 3 approved] F1000Research, 8, (doi: 10.12688/f1000research.19732.2)

Naumann, R. W., Hollebecque, A., Meyer, T., Devlin, M.-J., Oaknin, A., Kerger, J., López-Picazo, J. M., Machiels, J.-P., Delord, J.-P., Evans, T. R.J., Boni, V., Calvo, E., Topalian, S. L., Chen, T., Soumaoro, I., Li, B., Gu, J., Zwirtes, R., Moore, K. N. (2019) Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I/II CheckMate 358 trial. Journal of Clinical Oncology, 37, pp. 2825-2834. (doi: 10.1200/JCO.19.00739)

Macklin, P. S., Pillay, N., Lee, J. L., Pitman, H., Scott, S., Wang, J., Craig, C., Jones, J. L., Oien, K. A., Colling, R., Coupland, S. E., Verrill, C. (2019) CM-Path Molecular Diagnostics Forum—consensus statement on the development and implementation of molecular diagnostic tests in the United Kingdom. British Journal of Cancer, 121, pp. 738-743. (doi: 10.1038/s41416-019-0588-1)

Colling, R., Pitman, H., Oien, K., Rajpoot, N., Macklin, P., Snead, D., Sackville, T., Verrill, C. (2019) Artificial intelligence in digital pathology: a roadmap to routine use in clinical practice. Journal of Pathology, 249, pp. 143-150. (doi: 10.1002/path.5310)

Jones, R. L. et al. (2019) Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. European Journal of Cancer, 120, pp. 132-139. (doi: 10.1016/j.ejca.2019.07.024)

Bilsland, A. E., Liu, Y., Turnbull, A., Sumpton, D., Stevenson, K., Cairney, C. J., Boyd, S. M., Roffey, J., Jenkinson, D., Keith, W. N. (2019) A novel pyrazolopyrimidine ligand of human PGK1 and stress sensor DJ1 modulates the shelterin complex and telomere length regulation. Neoplasia, 21, pp. 893-907. (doi: 10.1016/j.neo.2019.07.008)

Vennin, C. et al. (2019) CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nature Communications, 10, (doi: 10.1038/s41467-019-10968-6)

Janssen, Q. P. et al. (2019) Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. Journal of the National Cancer Institute, 111, pp. 782-794. (doi: 10.1093/jnci/djz073)

Salati, M., Valeri, N., Spallanzani, A., Braconi, C., Cascinu, S. (2019) Oligometastatic gastric cancer: an emerging clinical entity with distinct therapeutic implications. European Journal of Surgical Oncology, 45, pp. 1479-1482. (doi: 10.1016/j.ejso.2018.11.006)

Salati, M., Caputo, F., Cunningham, D., Marcheselli, L., Spallanzani, A., Rimini, M., Gelsomino, F., Reggiani-Bonetti, L., Andrikou, K., Rovinelli, F., Smyth, E., Baratelli, C., Kouvelakis, K., Kalaitzaki, R., Gillbanks, A., Michalarea, V., Cascinu, S., Braconi, C. (2019) The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy. European Journal of Cancer, 117, pp. 84-90. (doi: 10.1016/j.ejca.2019.05.030)

Evans, T. R. J., Kudo, M., Finn, R. S., Han, K.-H., Cheng, A.-L., Ikeda, M., Kraljevic, S., Ren, M., Ductus, C. E., Piscaglia, F., Sung, M. W. (2019) Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma. British Journal of Cancer, 121, pp. 218-221. (doi: 10.1038/s41416-019-0506-6)

Reader, C. S., Vallath, S., Steele, C. W., Haider, S., Brentnall, A., Desai, A., Moore, K. M., Jamieson, N. B., Chang, D., Bailey, P., Scarpa, A., Lawlor, R., Chelala, C., Keyse, S. M., Biankin, A., Morton, J. P., Evans, T.R. J., Barry, S. T., Sansom, O. J., Kocher, H. M., Marshall, J. F. (2019) The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Journal of Pathology, 249, pp. 332-342. (doi: 10.1002/path.5320)

Seykora, T. F., Ecker, B. L., McMillan, M. T., Maggino, L., Beane, J. D., Fong, Z. V., Hollis, R. H., Jamieson, N. B., Javed, A. A., Kowalsky, S. J., Kunstman, J. W., Malleo, G., Poruk, K. E., Soares, K., Valero, V., Velu, L. K. P., Watkins, A. A., Vollmer, C. M. (2019) The beneficial effects of minimizing blood loss in pancreatoduodenectomy. Annals of Surgery, 270, pp. 147-157. (doi: 10.1097/SLA.0000000000002714)

Anandappa, G. et al. (2019) miR-31-3p expression and benefit from anti-EGFR inhibitors in metastatic colorectal cancer patients enrolled in the prospective phase II PROSPECT-C trial. Clinical Cancer Research, 25, pp. 3830-3838. (doi: 10.1158/1078-0432.ccr-18-3769)

Halbrook, C. J., Pontious, C., Kovalenko, I., Lapienyte, L., Dreyer, S., Lee, H.-J., Thurston, G., Zhang, Y., Lazarus, J., Sajjakulnukit, P., Hong, H. S., Kremer, D. M., Nelson, B. S., Kemp, S., Zhang, L., Chang, D., Biankin, A., Shi, J., Frankel, T. L., Crawford, H. C., Morton, J. P., Pasca di Magliano, M., Lyssiotis, C. A. (2019) Macrophage-released pyrimidines inhibit gemcitabine therapy in pancreatic cancer. Cell Metabolism, 29, pp. 1390-1399.e6. (doi: 10.1016/j.cmet.2019.02.001)

Brockmoeller, S., Young, C., Lee, J., Arends, M.J., Wilkins, B.S., Thomas, G.J., Oien, K.A., Jones, L., Hunter, K.D. (2019) Survey of UK histopathology consultants' attitudes towards academic and molecular pathology. Journal of Clinical Pathology, 72, pp. 399-405. (doi: 10.1136/jclinpath-2018-205568)

Clark, R., Oien, K., Roccisana, J., Bell, S., Sneddon, S. (2019) Curriculum Mapping and Pathology Teaching: A Novel Low Cost Mapping Method.

Banales, J. M., Cardinale, V., Macias, R., Andersen, J. B., Braconi, C., Carpino, G., Alvaro, D., Calvisi, D. F. (2019) Cholangiocarcinoma: state‐of‐the‐art knowledge and challenges. Liver International, 39, pp. 5-6. (doi: 10.1111/liv.14101)

Braconi, C., Roessler, S., Kruk, B., Lammert, F., Krawczyk, M., Andersen, J. B. (2019) Molecular perturbations in cholangiocarcinoma: is it time for precision medicine? Liver International, 39, pp. 32-42. (doi: 10.1111/liv.14085)

Neves, K. B., Rios, F. J., Jones, R., Evans, T. R. J., Montezano, A. C., Touyz, R. M. (2019) Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury. Cardiovascular Research, 115, pp. 978-988. (doi: 10.1093/cvr/cvz021)

Robinson, M., James, J., Thomas, G., West, N., Jones, L., Lee, J., Oien, K., Freeman, A., Craig, C., Sloan, P., Elliot, P., Cheang, M., Rodriguez-Justo, M., Verrill, C. (2019) Quality assurance guidance for scoring and reporting for pathologists and laboratories undertaking clinical trial work. Journal of Pathology: Clinical Research, 5, pp. 91-99. (doi: 10.1002/cjp2.121)

Rees, G., Salto-Tellez, M., Lee, J., Oien, K., Verrill, C., Freeman, A., Mirabile, I., West, N.P. (2019) Training and accreditation standards for pathologists undertaking clinical trial work. Journal of Pathology: Clinical Research, 5, pp. 100-107. (doi: 10.1002/cjp2.124)

Conway, J. R.W., Herrmann, D., Evans, T.R. J., Morton, J. P., Timpson, P. (2019) Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut, 68, pp. 742-758. (doi: 10.1136/gutjnl-2018-316822)

Dreyer, S. B., Jamieson, N. B., Evers, L., Duthie, F., Cooke, S., Marshall, J., Beraldi, D., Knight, S., Upstill-Goddard, R., Dickson, E. J., Carter, C. R., McKay, C. J., Biankin, A. V., Chang, D. K. (2019) Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. Chinese Clinical Oncology, 8, (doi: 10.21037/cco.2019.04.06)

Pell, R., Oien, K., Robinson, M., Pitman, H., Rajpoot, N., Rittscher, J., Snead, D., Verrill, C. (2019) The use of digital pathology and image analysis in clinical trials. Journal of Pathology: Clinical Research, 5, pp. 81-90. (doi: 10.1002/cjp2.127)

Twelves, C., Anthoney, A., Savulsky, C. I., Guo, M., Reyderman, L., Cresti, N., Semiglazov, V., Timcheva, C., Zubairi, I., Morrison, R., Plummer, R., Evans, T.R. J. (2019) A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine. British Journal of Cancer, 120, pp. 579-586. (doi: 10.1038/s41416-018-0366-5)

Anderson, R. L., Balasas, T., Callaghan, J., Coombes, R. C., Evans, J., Hall, J. A., Kinrade, S., Jones, D., Jones, P. S., Jones, R., Marshall, J. F., Panico, M. B., Shaw, J. A., Steeg, P. S., Sullivan, M., Tong, W., Westwell, A. D., Ritchie, J. W.A. (2019) A framework for the development of effective anti-metastatic agents. Nature Reviews Clinical Oncology, 16, pp. 185-204. (doi: 10.1038/s41571-018-0134-8)

Khan, K., Rane, J. K., Cunningham, D., Rao, S., Watkins, D., Starling, N., Kalaitzaki, E., Forster, M., Braconi, C., Valeri, N., Gerlinger, M., Chau, I. (2019) Efficacy and cardiotoxic safety profile of raltitrexed in fluoropyrimidines-pretreated or high-risk cardiac patients with GI malignancies: large single-center experience. Clinical Colorectal Cancer, 18, pp. 64-71.e1. (doi: 10.1016/j.clcc.2018.09.010)

Singh, G., Nahm, C. B., Jamieson, N. B., Chua, T. C., Wong, S., Thoo, C., Mittal, A., Gill, A. J., Samra, J. S. (2019) Management of post-pancreatectomy haemorrhage using resuscitative endovascular balloon occlusion of the aorta. Langenbeck's Archives of Surgery, 404, pp. 253-255. (doi: 10.1007/s00423-019-01759-0)

Strijker, M., Chen, J.W., Mungroop, T.H., Jamieson, N.B., van Eijck, C.H., Steyerberg, E.W., Wilmink, J.W., Groot Koerkamp, B., van Laarhoven, H.W., Besselink, M.G. (2019) Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer. British Journal of Surgery, 106, pp. 342-354. (doi: 10.1002/bjs.11111)

Nahm, C. B., Turchini, J., Jamieson, N., Moon, E., Sioson, L., Itchins, M., Arena, J., Colvin, E., Howell, V. M., Pavlakis, N., Clarke, S., Samra, J. S., Gill, A. J., Mittal, A. (2019) Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: a multi-institutional cohort study. European Journal of Surgical Oncology, 45, pp. 218-224. (doi: 10.1016/j.ejso.2018.10.050)

Maggino, L., Malleo, G., Bassi, C., Allegrini, V., Beane, J. D., Beckman, R. M., Chen, B., Dickson, E. J., Drebin, J. A., Ecker, B. L., Fraker, D. L., House, M. G., Jamieson, N. B., Javed, A. A., Kowalsky, S. J., Lee, M. K., McMillan, M. T., Roses, R. E., Salvia, R., Valero, V., Velu, L. K. P., Wolfgang, C. L., Zureikat, A. H., Vollmer, C. M. (2019) Identification of an optimal cut-off for drain fluid amylase on postoperative day 1 for predicting clinically relevant fistula after distal pancreatectomy. Annals of Surgery, 269, pp. 337-343. (doi: 10.1097/SLA.0000000000002532)

Salati, M., Braconi, C. (2019) Noncoding RNA in cholangiocarcinoma. Seminars in Liver Disease, 39, pp. 13-25. (doi: 10.1055/s-0038-1676097)

Fassan, M., Cui, R., Gasparini, P., Mescoli, C., Guzzardo, V., Vicentini, C., Munari, G., Loupakis, F., Lonardi, S., Braconi, C., Scarpa, M., D'Angelo, E., Pucciarelli, S., Angriman, I., Agostini, M., D'Incá, R., Farinati, F., Gafà, R., Lanza, G., Frankel, W. L., Croce, C. M., Valeri, N., Rugge, M. (2019) miR-224 is significantly upregulated and targets caspase-3 and caspase-7 during colorectal carcinogenesis. Translational Oncology, 12, pp. 282-291. (doi: 10.1016/j.tranon.2018.10.013)

Evans, T.R. J., Dean, E., Molife, L. R., Lopez, J., Ranson, M., El-Khouly, F., Zubairi, I., Savulsky, C., Reyderman, L., Jia, Y., Sweeting, L., Greystroke, A., Barriuso, J., Kristeleit, R. (2019) Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours. British Journal of Cancer, (doi: 10.1038/s41416-019-0377-x)

Ecker, B. L. et al. (2019) Risk factors and mitigation strategies for pancreatic fistula after distal pancreatectomy. Annals of Surgery, 269, pp. 143-149. (doi: 10.1097/SLA.0000000000002491)

Macklin, P. S., Hall, A., Lee, J., Hair, J., Spiers, V., Thomas, G. J., Oien, K. A., Verrill, C. (2018) Barriers to the release of human tissue for clinical trials research in the UK: a national survey of cellular pathology laboratories on behalf of the National Cancer Research Institute's Cellular Molecular Pathology (CM-Path) initiative. Journal of Clinical Pathology, 72, pp. 52-57. (doi: 10.1136/jclinpath-2018-205476)

Janjigian, Y. Y., Bendell, J., Calvo, E., Kim, J. W., Ascierto, P. A., Sharma, P., Ott, P. A., Peltola, K., Jaeger, D., Evans, J., de Braud, F., Chau, I., Harbison, C. T., Dorange, C., Tschaika, M., Le, D. T. (2018) CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. Journal of Clinical Oncology, 36, pp. 2836-2844. (doi: 10.1200/JCO.2017.76.6212)

Smit, S., Kwakkel, J., Keith, N. (2018) Accomplissh: creating societal impact from social sciences and humanities research. European Commission

Khan, K. H. et al. (2018) Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. Cancer Discovery, 8, pp. 1270-1285. (doi: 10.1158/2159-8290.CD-17-0891)

Lindsay, C. R. et al. (2018) Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. ESMO Open, 3, (doi: 10.1136/esmoopen-2018-000408)

Basu, B. et al. (2018) Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Annals of Oncology, 29, pp. 1918-1925. (doi: 10.1093/annonc/mdy245)

Krol, I., Castro-Giner, F., Maurer, M., Gkountela, S., Szczerba, B., Scherrer, R., Coleman, N., Carreira, S., Bachmann, F., Anderson, S., Engelhardt, M., Lane, H., Evans, T. R. J., Plummer, R., Kristeleit, R., Lopez, J., Aceto, N. (2018) Detection of circulating tumor cell clusters in human glioblastoma. British Journal of Cancer, 119, pp. 487-491. (doi: 10.1038/s41416-018-0186-7)

Khan, K. et al. (2018) Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. Gut, 67, pp. 1484-1492. (doi: 10.1136/gutjnl-2017-314178)

Baxter, M.A., Glen, H., Evans, T.R.J. (2018) Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma. Future Oncology, 14, pp. 2021-2029. (doi: 10.2217/fon-2017-0689)

Schofield, J. B., Oien, K. (2018) G167 Dataset for histopathological reporting of cancer of unknown primary (CUP) and malignancy of unknown primary origin (MUO)

Saraggi, D., Galuppini, F., Fanelli, G. N., Remo, A., Urso, E. D.L., Bao, R. Q., Bacchin, D., Guzzardo, V., Luchini, C., Braconi, C., Farinati, F., Rugge, M., Fassan, M. (2018) MiR-21 up-regulation in ampullary adenocarcinoma and its pre-invasive lesions. Pathology: Research and Practice, 214, pp. 835-839. (doi: 10.1016/j.prp.2018.04.018)

Candido, J. B. et al. (2018) CSF1R+ macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype. Cell Reports, 23, pp. 1448-1460. (doi: 10.1016/j.celrep.2018.03.131)

Williams, B. J., Lee, J., Oien, K. A., Treanor, D. (2018) Digital pathology access and usage in the UK: results from a national survey on behalf of the National Cancer Research Institute's CM-Path initiative. Journal of Clinical Pathology, 71, pp. 463-466. (doi: 10.1136/jclinpath-2017-204808)

Convertino, M., Church, T. R., Olsen, G. W., Liu, Y., Doyle, E., Elcombe, C. R., Barnett, A. L., Samuel, L. M., MacPherson, I. R., Evans, T. R.J. (2018) Stochastic pharmacokinetic-pharmacodynamic modeling for assessing the systemic health risk of perfluorooctanoate (PFOA) Toxicological Sciences, 163, pp. 293-306. (doi: 10.1093/toxsci/kfy035)

Carvajal, R. D. et al. (2018) Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicentre, randomised trial (SUMIT) Journal of Clinical Oncology, 36, pp. 1232-1239. (doi: 10.1200/JCO.2017.74.1090)

Ecker, B. L. et al. (2018) Characterization and optimal management of high-risk pancreatic anastomoses during pancreatoduodenectomy. Annals of Surgery, 267, pp. 608-616. (doi: 10.1097/SLA.0000000000002327)

Moore, D. A., Young, C. A., Morris, H. T., Oien, K. A., Lee, J. L., Jones, J. L., Salto-Tellez, M. (2018) Time for change: a new training programme for morpho-molecular pathologists? Journal of Clinical Pathology, 71, pp. 285-290. (doi: 10.1136/jclinpath-2017-204821)

Kudo, M., Finn, R., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., Blanc, J. F., Vogel, A., Komov, D., Evans, J., Lopez, C., Dutcus, C., Guo, M., Saito, K., Kraljevic, S., Tamai, T., Ren, M., Cheng, A.-L. (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet, 391, pp. 1163-1173. (doi: 10.1016/S0140-6736(18)30207-1)

Ali, A., Ali, Z., Yousafzai, Y. M., Oien, K. A. (2018) Cancer biomarker development from basic science to clinical practice. Journal of Postgraduate Medical Institute, 32, pp. 3-8.

Marchetti, C., Zyner, K. G., Ohnmacht, S. A., Robson, M., Haider, S. M., Morton, J. P., Marsico, G., Vo, T., Laughlin-Toth, S., Ahmed, A. A., Di Vita, G., Pazitna, I., Gunaratnam, M., Besser, R. J., Andrade, A. C.G., Diocou, S., Pike, J. A., Tannahill, D., Pedley, R. B., Evans, T.R. J., Wilson, W. D., Balasubramanian, S., Neidle, S. (2018) Targeting multiple effector pathways in pancreatic ductal adenocarcinoma with a G-quadruplex-binding small molecule. Journal of Medicinal Chemistry, 61, pp. 2500-2517. (doi: 10.1021/acs.jmedchem.7b01781)

Cook, N., Basu, B., Smith, D.-M., Gopinathan, A., Evans, T.R. J., Steward, W. P., Palmer, D., Propper, D., Venugopal, B., Hategan, M., Anthoney, D. A., Hampson, L. V., Nebozhyn, M., Tuveson, D., Farmer-Hall, H., Turner, H., McLeod, R., Halford, S., Jodrell, D. (2018) A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer, 118, pp. 793-801. (doi: 10.1038/bjc.2017.495)

Lampis, A. et al. (2018) MIR21 drives resistance to heat shock protein 90 inhibition in cholangiocarcinoma. Gastroenterology, 154, pp. 1066-1079.e5. (doi: 10.1053/j.gastro.2017.10.043)

Vlachogiannis, G. et al. (2018) Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 359, pp. 920-926. (doi: 10.1126/science.aao2774)

Wilson, R. A.M., Evans, T.R. J., Fraser, A. R., Nibbs, R. J.B. (2018) Immune checkpoint inhibitors: new strategies to checkmate cancer. Clinical and Experimental Immunology, 191, pp. 133-148. (doi: 10.1111/cei.13081)

Sclafani, F., Chau, I., Cunningham, D., Hahne, J. C., Vlachogiannis, G., Eltahir, Z., Lampis, A., Braconi, C., Kalaitzaki, E., De Castro, D. G., Wotherspoon, A., Capdevila, J., Glimelius, B., Tarazona, N., Begum, R., Lote, H., Hulkki Wilson, S., Mentrasti, G., Brown, G., Tait, D., Oates, J., Valeri, N. (2018) KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. Scientific Reports, 8, (doi: 10.1038/s41598-018-19212-5)

Dreyer, S.B., Jamieson, N.B., Upstill-Goddard, R., Bailey, P.J., McKay, C.J., Australian Pancreatic Cancer Genome Initiative, , Biankin, A.V., Chang, D.K. (2018) Defining the molecular pathology of pancreatic body and tail adenocarcinom. British Journal of Surgery, 105, pp. e183-e191. (doi: 10.1002/bjs.10772)

Moorcraft, S. Y., Gonzalez de Castro, D., Cunningham, D., Jones, T., Walker, B. A., Peckitt, C., Yuan, L. C., Frampton, M., Begum, R., Eltahir, Z., Wotherspoon, A., Teixeira Mendes, L. S., Hulkki Wilson, S., Gillbanks, A., Baratelli, C., Fotiadis, N., Patel, A., Braconi, C., Valeri, N., Gerlinger, M., Rao, S., Watkins, D., Chau, I., Starling, N. (2018) Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice. Annals of Oncology, 29, pp. 230-236. (doi: 10.1093/annonc/mdx631)

Ecker, B. L. et al. (2018) Pancreatogastrostomy vs. pancreatojejunostomy: a risk-stratified analysis of 5316 pancreatoduodenectomies. Journal of Gastrointestinal Surgery, 22, pp. 68-76. (doi: 10.1007/s11605-017-3547-2)

Keith, W. N., Yu, X., Barbeau, R.-M. (2018) Diversity of institutional support for research impact implementation. Zeitschrift für Diversitätsforschung und –management, 3, pp. 199-207.

Balachandran, V. P. et al. (2017) Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 551, pp. 512-516. (doi: 10.1038/nature24462)

Jones, J. L., Oien, K. A., Lee, J. L., Salto-Tellez, M. (2017) Morphomolecular pathology: setting the framework for a new generation of pathologists. British Journal of Cancer, 117, pp. 1581-1582. (doi: 10.1038/bjc.2017.340)

Ghidini, M., Cascione, L., Carotenuto, P., Lampis, A., Trevisani, F., Previdi, M. C., Hahne, J. C., Said-Huntingford, I., Raj, M., Zerbi, A., Mescoli, C., Cillo, U., Rugge, M., Roncalli, M., Torzilli, G., Rimassa, L., Santoro, A., Valeri, N., Fassan, M., Braconi, C. (2017) Characterisation of the immune-related transcriptome in resected biliary tract cancers. European Journal of Cancer, 86, pp. 158-165. (doi: 10.1016/j.ejca.2017.09.005)

Scarpa, A. et al. (2017) Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 550, pp. 548. (doi: 10.1038/nature24026)

Ghidini, M., Tomasello, G., Botticelli, A., Barni, S., Zabbialini, G., Seghezzi, S., Passalacqua, R., Braconi, C., Petrelli, F. (2017) Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. HPB, 19, pp. 741-748. (doi: 10.1016/j.hpb.2017.05.010)

Cairney, C. J., Godwin, L. S., Bilsland, A. E., Burns, S., Stevenson, K. H., McGarry, L., Revie, J., Moore, J. D., Wiggins, C. M., Collinson, R. S., Mudd, C., Tsonou, E., Sadaie, M., Bennett, D. C., Narita, M., Torrance, C. J., Keith, W. N. (2017) A 'synthetic-sickness' screen for senescence re-engagement targets in mutant cancer backgrounds. PLoS Genetics, 13, (doi: 10.1371/journal.pgen.1006942)

Meyer, T., Fox, R., Ma, Y. T., Ross, P. J., James, M. W., Sturgess, R., Stubbs, C., Stocken, D. D., Wall, L., Watkinson, A., Hacking, N., Evans, T.R. J., Collins, P., Hubner, R. A., Cunningham, D., Primrose, J. N., Johnson, P. J., Palmer, D. H. (2017) Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterology and Hepatology, 2, pp. 565-575. (doi: 10.1016/S2468-1253(17)30156-5)

Grose, D., McIntosh, D., Jamieson, N., Carter, R., Dickson, E., Chang, D., Marashi, H., Wilson, C., Alfayez, M., Kerr, A., O’Donoghue, R., Haskins, L., Duthie, F., McKay, C. J., Graham, J. (2017) The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. Journal of Gastrointestinal Oncology, 8, pp. 683-695. (doi: 10.21037/jgo.2017.04.01)

Kayhanian, H., Smyth, E. C., Braconi, C. (2017) Emerging molecular targets and therapy for cholangiocarcinoma. World Journal of Gastrointestinal Oncology, 9, pp. 268-280. (doi: 10.4251/wjgo.v9.i7.268)

Wong, N. A.C.S., Adamczyk, L. A., Evans, S., Cullen, J., Oniscu, A., Oien, K. A. (2017) A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of colorectal carcinoma. Histopathology, 71, pp. 34-41. (doi: 10.1111/his.13194)

de la Cruz-Merino, L., Di Guardo, L., Grob, J.-J., Venosa, A., Larkin, J., McArthur, G. A., Ribas, A., Acierto, P. A., Evans, J. T.R., Gomez‑Escobar, A., Barteselli, G., Eng, S., Hsu, J. J., Uyei, A., Dréno, B. (2017) Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. Journal of Translational Medicine, 15, (doi: 10.1186/s12967-017-1246-0)

Lote, H. et al. (2017) Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer. Annals of Oncology, 28, pp. 1243-1249. (doi: 10.1093/annonc/mdx074)

Abbosh, C. et al. (2017) Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 545, pp. 446-451. (doi: 10.1038/nature22364)

Pepe, F., Pagotto, S., Soliman, S., Rossi, C., Lanuti, P., Braconi, C., Mariani-Costantini, R., Visone, R., Veronese, A. (2017) Regulation of miR-483-3p by the O-linked N-acetylglucosamine transferase links chemosensitivity to glucose metabolism in liver cancer cells. Oncogenesis, 6, (doi: 10.1038/oncsis.2017.35)

McMillan, M. T. et al. (2017) Incorporation of procedure-specific risk into the ACS-NSQIP surgical risk calculator improves the prediction of morbidity and mortality after pancreatoduodenectomy. Annals of Surgery, 265, pp. 978-986. (doi: 10.1097/SLA.0000000000001796)

Dreyer, S. B., Powell, A. G.M.T., McSorley, S. T., Waterston, A., Going, J. J., Edwards, J., McMillan, D. C., Horgan, P. G. (2017) The pretreatment systemic inflammatory response is an important determinant of poor pathologic response for patients undergoing neoadjuvant therapy for rectal cancer. Annals of Surgical Oncology, 24, pp. 1295-1303. (doi: 10.1245/s10434-016-5684-3)

Johns, A. L. et al. (2017) Lost in translation: returning germline genetic results in genome-scale cancer research. Genome Medicine, 9, (doi: 10.1186/s13073-017-0430-4)

Vennin, C. et al. (2017) Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Science Translational Medicine, 9, (doi: 10.1126/scitranslmed.aai8504)

Dreyer, S. B., Chang, D. K., Bailey, P., Biankin, A. V. (2017) Pancreatic cancer genomes: implications for clinical management and therapeutic development. Clinical Cancer Research, 23, pp. 1638-1646. (doi: 10.1158/1078-0432.CCR-16-2411)

King, J., Palmer, D.H., Johnson, P., Ross, P., Hubner, R.A., Sumpter, K., Darby, S., Braconi, C., Iwuji, C., Swinson, D., Collins, P., Patel, K., Nobes, J., Muazzam, I., Blesing, C., Kirkwood, A., Nash, S., Meyer, T. (2017) Sorafenib for the treatment of advanced hepatocellular cancer – a UK audit. Clinical Oncology, 29, pp. 256-262. (doi: 10.1016/j.clon.2016.11.012)

Letsolo, B. T., Jones, R. E., Rowson, J., Grimstead, J. W., Keith, W. N., Jenkins, G. J.S., Baird, D. M. (2017) Extensive telomere erosion is consistent with localised clonal expansions in Barrett's metaplasia. PLoS ONE, 12, (doi: 10.1371/journal.pone.0174833)

Wilson, R. H., Evans, T.R. J., Middleton, M. R., Molife, L. R., Spicer, J., Dieras, V., Roxburgh, P., Giordano, H., Jaw-Tsai, S., Goble, S., Plummer, R. (2017) A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. British Journal of Cancer, 116, (doi: 10.1038/bjc.2017.36)

Scarpa, A. et al. (2017) Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 543, pp. 65-71. (doi: 10.1038/nature21063)

Jamieson, N.B., Maker, A.V. (2017) Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Therapy, 24, pp. 134-140. (doi: 10.1038/cgt.2016.63)

Previdi, M. C., Carotenuto, P., Zito, D., Pandolfo, R., Braconi, C. (2017) Noncoding RNAs as novel biomarkers in pancreatic cancer: what do we know? Future Oncology, 13, pp. 443-453. (doi: 10.2217/fon-2016-0253)

Evans, T.R.J., Van Cutsem, E., Moore, M.J., Bazin, I.S., Rosemurgy, A., Bodoky, G., Deplanque, G., Harrison, M., Melichar, B., Pezet, D., Elekes, A., Rock, E., Lin, C., Strauss, L., O'Dwyer, P.J. (2017) Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. Annals of Oncology, 28, pp. 354-361. (doi: 10.1093/annonc/mdw607)

Jones, W., Allardice, G., Scott, I., Oien, K., Brewster, D., Morrison, D. S. (2017) Cancers of unknown primary diagnosed during hospitalization: a population-based study. BMC Cancer, 17, (doi: 10.1186/s12885-017-3083-1)

Humphris, J. L. et al. (2017) Hypermutation in pancreatic cancer. Gastroenterology, 152, pp. 68-74.e2. (doi: 10.1053/j.gastro.2016.09.060)

Soria, J.C., Gan, H.K., Blagden, S.P., Plummer, R., Arkenau, H.T., Ranson, M., Evans, T.R.J., Zalcman, G., Bahleda, R., Hollebecque, A., Lemech, C., Dean, E., Brown, J., Gibson, D., Peddareddigari, V., Murray, S., Nebot, N., Mazumdar, J., Swartz, L., Auger, K.R., Fleming, R.A., Singh, R., Millward, M. (2016) A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Annals of Oncology, 27, pp. 2268-2274. (doi: 10.1093/annonc/mdw427)

Driscoll, D. R., Karim, S. A., Sano, M., Gay, D. M., Jacob, W., Yu, J., Mizukami, Y., Gopinathan, A., Jodrell, D. I., Evans, T.R. J., Bardeesy, N., Hall, M. N., Quattrochi, B. J., Klimstra, D. S., Barry, S. T., Sansom, O. J., Lewis, B. C., Morton, J. P. (2016) mTORC2 signaling drives the development and progression of pancreatic cancer. Cancer Research, 76, pp. 6911-6923. (doi: 10.1158/0008-5472.CAN-16-0810)

Trevisani, F., Ghidini, M., Larcher, A., Lampis, A., Lote, H., Manunta, P., Alibrandi, M. T. S., Zagato, L., Citterio, L., Dell'Antonio, G., Carenzi, C., Capasso, G., Rugge, M., Rigotti, P., Bertini, R., Cascione, L., Briganti, A., Salonia, A., Benigni, F., Braconi, C., Fassan, M., Hahne, J. C., Montorsi, F., Valeri, N. (2016) MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. British Journal of Cancer, 115, pp. 1343-1350. (doi: 10.1038/bjc.2016.329)

Edeline, J., Blanc, J.-F., Johnson, P., Campillo-Gimenez, B., Ross, P., Ma, Y. T., King, J., Hubner, R. A., Sumpter, K., Darby, S., Evans, J., Iwuji, C., Swinson, D., Collins, P., Patel, K., Muazzam, I., Palmer, D. H., Meyer, T. (2016) A multicenter comparison between Child Pugh and ALBI scores in patients treated with sorafenib for hepatocellular carcinoma. Liver International, 36, pp. 1821-1828. (doi: 10.1111/liv.13170)

Jamieson, D., Griffin, M. J., Sludden, J., Drew, Y., Cresti, N., Swales, K., Merriman, M., Allen, R., Bevan, P., Buerkle, M., Mala, C., Coyle, V., Rodgers, L., Dean, E., Greystoke, A., Banerji, U., Wilson, R. H., Evans, T.R. J., Anthoney, A., Ranson, M., Boddy, A. V., Plummer, R. (2016) A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. European Journal of Cancer, 68, pp. 1-10. (doi: 10.1016/j.ejca.2016.08.026)

Propper, D., Jones, K., Anthoney, D. A., Mansoor, W., Ford, D., Eatock, M., Agarwal, R., Inatani, M., Saito, M., Evans, T.R. J. (2016) Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. BMC Cancer, 16, (doi: 10.1186/s12885-016-2828-6)

Zhu, A. X., Kang, Y.-K., Rosmorduc, O., Evans, T.R. J., Santoro, A., Ross, P., Gane, E., Vogel, A., Jeffers, M., Meinhardt, G., Peña, C. E.A. (2016) Biomarker analyses of clinical outcomes in patients with advanced hepatocellular carcinoma treated with Sorafenib with or without Erlotinib in the SEARCH Trial. Clinical Cancer Research, 22, pp. 4870-4879. (doi: 10.1158/1078-0432.CCR-15-2883)

Sclafani, F., Chau, I., Cunningham, D., Lampis, A., Hahne, J. C., Ghidini, M., Lote, H., Zito, D., Tabernero, J., Glimelius, B., Cervantes, A., Begum, R., De Castro, D. G., Wilson, S. H., Peckitt, C., Eltahir, Z., Wotherspoon, A., Tait, D., Brown, G., Oates, J., Braconi, C., Valeri, N. (2016) Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. Carcinogenesis, 37, pp. 852-857. (doi: 10.1093/carcin/bgw073)

Aparicio, T., Zaanan, A., Mary, F., Afchain, P., Manfredi, S., Evans, T. R. J. (2016) Small bowel adenocarcinoma. Gastroenterology Clinics of North America, 45, pp. 447-457. (doi: 10.1016/j.gtc.2016.04.004)

Bilsland, A. E., Spiliopoulou, P., Evans, T.R. J. (2016) Virotherapy: cancer gene therapy at last? F1000Research, 5, (doi: 10.12688/f1000research.8211.1)

Smyth, E. C., Fassan, M., Cunningham, D., Allum, W. H., Okines, A. F.C., Lampis, A., Hahne, J. C., Rugge, M., Peckitt, C., Nankivell, M., Langley, R., Ghidini, M., Braconi, C., Wotherspoon, A., Grabsch, H. I., Valeri, N. (2016) Effect of pathologic tumor response and nodal status on survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy trial. Journal of Clinical Oncology, 34, pp. 2721-2727. (doi: 10.1200/JCO.2015.65.7692)

Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., Morse, M. A., Ascierto, P. A., Horn, L., Amin, A., Pillai, R. N., Evans, J., Chau, I., Bono, P., Atmaca, A., Sharma, P., Harbison, C. T., Lin, C.-S., Christensen, O., Calvo, E. (2016) Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncology, 17, pp. 883-895. (doi: 10.1016/S1470-2045(16)30098-5)

Steele, C. W. et al. (2016) CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell, 29, pp. 832-845. (doi: 10.1016/j.ccell.2016.04.014)

Milojkovic Kerklaan, B., Slater, S., Flynn, M., Greystoke, A., Witteveen, P. O., Megui-Roelvink, M., de Vos, F., Dean, E., Reyderman, L., Ottesen, L., Ranson, M., Lolkema, M. P. J., Plummer, R., Kristeleit, R., Evans, T. R. J., Schellens, J. H. M. (2016) A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors. Investigational New Drugs, 34, pp. 329-337. (doi: 10.1007/s10637-016-0344-9)

Lupini, L., Pepe, F., Ferracin, M., Braconi, C., Callegari, E., Pagotto, S., Spizzo, R., Zagatti, B., Lanuti, P., Fornari, F., Ghasemi, R., Mariani-Costantini, R., Bolondi, L., Gramantieri, L., Calin, G. A., Sabbioni, S., Visone, R., Veronese, A., Negrini, M. (2016) Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. Oncotarget, 7, pp. 31361-31371. (doi: 10.18632/oncotarget.8913)

Jabbar, S.A.A., Jamieson, N.B., Morris, A.J., Oien, K.A., Duthie, F., McKay, C.J., Carter, C.R., Dickson, E.J. (2016) A Glasgow tipple-transjugular intrahepatic portosystemic shunt insertion prior to Whipple resection. Journal of Surgical Case Reports, 2016, (doi: 10.1093/jscr/rjw089)

Palani Velu, L.K., McKay, C.J., Carter, C.R., McMillan, D.C., Jamieson, N.B., Dickson, E.J. (2016) Serum amylase and C-reactive protein in risk stratification of pancreas-specific complications after pancreaticoduodenectomy. British Journal of Surgery, 103, pp. 553-563. (doi: 10.1002/bjs.10098)

Khan, K., Cunningham, D., Peckitt, C., Barton, S., Tait, D., Hawkins, M., Watkins, D., Starling, N., Rao, S., Begum, R., Thomas, J., Oates, J., Guzzardo, V., Fassan, M., Braconi, C., Chau, I. (2016) miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. Oncotarget, 7, pp. 12672-12681. (doi: 10.18632/oncotarget.7208)

Graham, J.S., Boyd, K., Coxon, F.Y., Wall, L.R., Eatock, M.M., Maughan, T.S., Highley, M., Soulis, E., Conway, F., Evans, T. (2016) A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract. BMC Research Notes, 9, (doi: 10.1186/s13104-015-1778-4)

Bailey, P. et al. (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 531, pp. 47-52. (doi: 10.1038/nature16965)

Gingras, M.-C. et al. (2016) Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation. Cell Reports, 14, pp. 907-919. (doi: 10.1016/j.celrep.2015.12.005)

Erami Rud Majani, Z. et al. (2016) Intravital FRAP imaging using an E-cadherin-GFP mouse reveals disease- and drug-dependent dynamic regulation of cell-cell junctions in live tissue. Cell Reports, 14, pp. 152-167. (doi: 10.1016/j.celrep.2015.12.020)

Ali, A., Bell, S., Bilsland, A., Slavin, J., Lynch, V., Elgoweini, M., Derakhshan, M. H., Jamieson, N. B., Chang, D., Brown, V., Denley, S., Orange, C., McKay, C., Carter, R., Oien, K. A., Duthie, F. R. (2016) Investigating various thresholds as immunohistochemistry cutoffs for observer agreement. Applied Immunohistochemistry and Molecular Morphology, 25, pp. 599-608. (doi: 10.1097/PAI.0000000000000357)

Carotenuto, P. et al. (2016) Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. Gut, 66, pp. 1268-1277. (doi: 10.1136/gutjnl-2016-312278)